Who Paid My Doc
Charbel Salamon
Urogynecology and Reconstructive Pelvic Surgery Orlando, FL Medical Doctor
NPI 1316033483 CMS profile 371777
21 Columbia St, Orlando, FL 32806
General payments
$100,099
Research payments
$4,004
Ownership & investment interest
$0
Research they led as principal investigator
$37,061
Through program year 2025, Charbel Salamon of Orlando, FL is reported in the CMS Open Payments database as having received $100,099 across 108 general payments and $4,004 in research payments paid to them. Separately, studies naming them as principal investigator received $37,061 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 96th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $5,439 | 11 | |
| 2024 | General | $19,338 | 23 | |
| 2023 | General | $9,814 | 14 | |
| 2022 | General | $12,529 | 27 | |
| 2021 | General | $27,324 | 15 | |
| 2021 | Research | $750 | 1 | |
| 2020 | General | $12,058 | 9 | |
| 2020 | Research | $1,635 | 1 | |
| 2019 | General | $13,598 | 9 | |
| 2019 | Research | $1,619 | 2 |
Beside peers
- Charbel Salamon
- Urogynecology and Reconstructive Pelvic Surgery median
- Middle half of Urogynecology and Reconstructive Pelvic Surgery
- National median
In program year 2025, general payments to Charbel Salamon were reported at $5,439. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.
Show as a table
| Year | Charbel Salamon | Urogynecology and Reconstructive Pelvic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $13,598 | $358 | $132–$1,270 | $163 |
| 2020 | $12,058 | $198 | $86–$642 | $114 |
| 2021 | $27,324 | $361 | $118–$1,182 | $132 |
| 2022 | $12,529 | $410 | $128–$1,175 | $149 |
| 2023 | $9,814 | $434 | $152–$1,344 | $160 |
| 2024 | $19,338 | $494 | $193–$1,331 | $164 |
| 2025 | $5,439 | $412 | $133–$1,300 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 18 drugsPart D claims
803
Drug cost
$56,249
Branded share of claims
35%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Estradiol | Generic | 313 | $22,717 | |
| Myrbetriq Mirabegron | Brand | 24 | $12,368 | |
| Gemtesa Vibegron | Brand | 16 | $12,227 | |
| Yuvafem Estradiol | Brand | 16 | $1,992 | |
| Methenamine Hippurate | Generic | 30 | $1,883 | |
| Nitrofurantoin Nitrofurantoin Macrocrystal | Brand | 45 | $1,516 | |
| Oxybutynin Chloride Er Oxybutynin Chloride | Brand | 33 | $785 | |
| Trimethoprim | Generic | 11 | $738 | |
| Cephalexin | Generic | 65 | $537 | |
| Metoprolol Tartrate | Generic | 19 | $347 |
The 10 drugs with the highest cost, of 18 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 35 billing codesPaid by Medicare
$75,230
Medicare patients
106
Services billed
1,425
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 73% | |
| Arthritis | 65% | |
| Osteoporosis | 33% | |
| Diabetes | 30% | |
| Depression | 29% | |
| Ischemic heart disease | 26% | |
| Chronic kidney disease | 26% | |
| Atrial fibrillation | 15% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
112 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Urogynecology and Reconstructive Pelvic Surgery in Florida
Nathan Kow
Urogynecology and Reconstructive Pelvic Surgery · Orlando, FL
Amir Shariati
Urogynecology and Reconstructive Pelvic Surgery · Coconut Creek, FL
Allison Wyman
Urogynecology and Reconstructive Pelvic Surgery · Tampa, FL
Jose Lazaro Weiss
Urogynecology and Reconstructive Pelvic Surgery · Oviedo, FL
Paul Pettit
Urogynecology and Reconstructive Pelvic Surgery · Jacksonville, FL
Arash Rahi
Urogynecology and Reconstructive Pelvic Surgery · Coconut Creek, FL
Related records
Urogynecology and Reconstructive Pelvic Surgery in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Urogynecology and Reconstructive Pelvic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.